Latest Articles
‘Breakthrough’ blood test for endometriosis: Study - RACGP
‘Breakthrough’ blood test for endometriosis: Study RACGP
Published: Jan. 6, 2025, 5:32 a.m.
Human endometrial stem cell-derived small extracellular vesicles enhance neurite outgrowth and peripheral nerve regeneration through activating the PI3K/AKT signaling pathway - Journal of Translational Medicine
Human endometrial stem cell-derived small extracellular vesicles enhance neurite outgrowth and peripheral nerve regeneration through activating the PI3K/AKT signaling pathway Journal of Translational Medicine
Published: Jan. 3, 2025, 9:53 p.m.
‘Breakthrough’ blood test could spot ‘fingerprints’ of chronic condition affecting millions - The Mirror
‘Breakthrough’ blood test could spot ‘fingerprints’ of chronic condition affecting millions The Mirror
Published: Jan. 3, 2025, 2:44 p.m.
Australian researchers make breakthrough in endometriosis detection - MSN
Australian researchers make breakthrough in endometriosis detection MSN
Published: Dec. 31, 2024, 10:08 a.m.
Australian researchers make breakthrough in endometriosis detection - Sky News Australia
Australian researchers make breakthrough in endometriosis detection Sky News Australia
Published: Dec. 31, 2024, 12:33 a.m.
Proteomics International Laboratories Ltd (ASX:PIQ) Breakthrough Results for Endometriosis Diagnostic Blood Test - ABN Newswire
Proteomics International Laboratories Ltd (ASX:PIQ) Breakthrough Results for Endometriosis Diagnostic Blood Test ABN Newswire
Published: Dec. 29, 2024, 10:22 p.m.
Proteomics $2.16m R&D rebate fuels breakthrough blood tests - MSN
Proteomics $2.16m R&D rebate fuels breakthrough blood tests MSN
Published: Dec. 16, 2024, 4:40 a.m.
Proteomics $2.16m R&D rebate fuels breakthrough blood tests - Brisbane Times
Proteomics $2.16m R&D rebate fuels breakthrough blood tests Brisbane Times
Published: Dec. 16, 2024, 4:17 a.m.
Proteomics $2.16m R&D rebate fuels breakthrough blood tests - The Age
Proteomics $2.16m R&D rebate fuels breakthrough blood tests The Age
Published: Dec. 16, 2024, 4:17 a.m.
IDEAYA Launches Breakthrough Phase 1 Trial: Novel PARG Inhibitor + KEYTRUDA for Endometrial Cancer - StockTitan
IDEAYA Launches Breakthrough Phase 1 Trial: Novel PARG Inhibitor + KEYTRUDA for Endometrial Cancer StockTitan
Published: Dec. 10, 2024, 11 a.m.
Link copied to clipboard!